KYMAB LIMITED
Company number 07027523 · Monitor this company
Executive summary
KYMAB LIMITED operates within the highly capital-intensive UK biotechnology sector, leveraging its proprietary Kymouse platform to maintain a strong competitive position in antibody therapeutics. While typical biotechs face severe cash burn and funding cliffs, Kymab's integration into a larger pharmaceutical group structure provides significant financial stability, allowing it to outperform many standalone peers within the Cambridge innovation cluster.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2009-09-23
- Registered office
- The Eddeva Building (B920), Babraham Research Campus, Cambridge, England, CB22 3AT
- Postcode
- CB22 3AT
- Capital
- 60,924 GBP
- Accounts category
- Full
Accounts
- Last made up to
- 2025-12-31
- Next due by
- 2027-09-30
- Financial year end
- 31 December
Confirmation statement
- Last statement dated
- 2026-09-23
- Next due by
- 2027-10-07
Nature of business (SIC)
- 74909 Other professional, scientific and technical activities not elsewhere classified
Officers 5 current · 19 resigned
Group structure 3 subsidiaries
Controlled by KYMAB GROUP LIMITED — since 2016-11-23
-
14M GENOMICS LIMITED Dissolved
-
KYMAB ACCESS LIMITED Dissolved
-
KYMAB EBT LIMITED Dissolved
From persons-with-significant-control filings on the public register.
Contact details
- Website
- kymab.com
Previous registered addresses 2
| Address | Changed on |
|---|---|
| MEDITRINA (B260), BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, CB22 3AT | 2014-11-04 |
| SEVENTH FLOOR 90 HIGH HOLBORN, LONDON, WC1V 6XX | 2010-07-23 |
Among its peers
Among the oldest 25%
of 676 similar companies in CB, trading since 2009
The class of 2009
30%
of the 4,529 companies in this sector incorporated in 2009 are still active today; 67% have since been dissolved.
A fact about the year, not a forecast for this company.